Final Overall Survival Analysis of the PROSPER Trial in Nonmetastatic Castration-Resistant Prostate Cancer – Karim Fizazi

Speaking with Alicia Morgans, Karim Fizazi discusses the final overall survival analysis of the PROSPER study in nonmetastatic castration-resistant prostate cancer. Enzalutamide has previously been shown to postpone the time to metastasis or death. Data presented at ASCO 2020 demonstrated that overall survival is significantly improved in patients receiving enzalutamide — median overall…

Read the full article here

Source: UroToday

Categories: Latest Headlines, Urology

Tags: PROSPER, ProstateCancer

Tweets with this article

UroToday.com

Final overall survival analysis of the #PROSPER trial in nonmetastatic castration-resistant #ProstateCancer. Karim Fizazi, MD, PhD @GustaveRoussy joins @CaPsurvivorship @NUFeinbergMed in a discussion on UroToday > https://t.co/JxDGautM3W https://t.co/Oz9sHI3Cu7

APCCC 2024: Management of Frail Patients with mHSPC

APCCC 2024, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), Management of Frail Patients with mHSPC, M1 disease, abiraterone, prednisolone, abiraterone plus prednisolone, androgen deprivation…

UroToday.com April 26, 2024

APCCC 2024: Management of Patients with mHSPC and Early Progression on Combination Therapy

APCCC 2024, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), mHSPC and early progression on combination therapy, androgen deprivation therapy (ADT), abiraterone, enzalutamide, apalutamide, darolutamide,…

UroToday.com April 26, 2024

APCCC 2024: Genomic Classifiers and Artificial Intelligence as Predictors for Treatment Benefit

APCCC 2024 advanced prostate cancer, use of genomic classifiers and artificial intelligence tools as predictors of treatment benefit in prostate cancer patients, prostate cancer mortality,…

UroToday.com April 26, 2024

APCCC 2024: Which Patients with mHSPC Can Be Offered a Treatment Break (De-Escalation Strategies) and How to Manage the Break?

APCCC 2024 management of mHSPC, EMA established the Cancer Medicines Forum, androgen deprivation and continuing the ARTA, LIBERTAS study, EMBARK, DE-ESCALATE EORTC 2238 trial, intermittent…

UroToday.com April 26, 2024

APCCC 2024: Update on the IRONMAN Project

APCCC 2024 update on the IRONMAN project, IRONMAN Executive Committee, treatment of advanced prostate cancer, Engaging Men in Patient Reported Outcomes, PROfound study, abiraterone, enzalutamide,…

UroToday.com April 26, 2024

APCCC 2024: Escalation Strategies in Patients with mHSPC and an Unfavourable PSA Decline – Is More Better?

APCCC 2024, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), Escalation Strategies in Patients with mHSPC, Unfavourable PSA Decline, PSA progression, radiographic progression, clinical progression,…

UroToday.com April 26, 2024

APCCC 2024: In Which Patients with Metachronous Low-volume mHSPC Do You Recommend “total Therapy”?

APCCC 2024 metastatic hormone-sensitive prostate cancer (mHSPC), metachronous low-volume mHSPC, ‘total therapy’ with metastasis-directed therapy (MDT), ‘Pokemet’ approach,

UroToday.com April 26, 2024

APCCC 2024: Debate: How to Best Manage a Fit Patient with High-Risk Localised and Locally Advanced Prostate Cancer? Surgery as Radical Local Treatment (As Part of a Multimodality Approach)

APCCC 2024, Advanced Prostate Cancer, radical prostatectomy, pelvic lymph node dissection, cN1 disease, Extended pelvic lymph node dissection, RAVES trial, RADICALS-RT trial, GETUG 17 trial,…

UroToday.com April 26, 2024

APCCC 2024: Radiation Therapy Schedules and Fields for High-Risk and Locally Advanced Prostate Cancer

APCCC 2024, prostate cancer, Radiation Therapy Schedules for prostate cancer, Locally Advanced Prostate Cancer, GETUG-AFU 18 trial, dose-escalated external beam radiotherapy, ultrahypofractionation, ultrahypofractionation via stereotactic…

UroToday.com April 26, 2024

APCCC 2024: Should the Primary Be Treated in Synchronous High-Volume mHSPC

APCCC 2024 management of metastatic hormone sensitive prostate cancer (mHSPC), synchronous high-volume mHSPC, HORRAD trial, de novo mHSPC, STAMPEDE Arm H, STOPCAP collaboration.

UroToday.com April 26, 2024

Related Articles